Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Pieris Pharmaceuticals Inc.
DescriptionIL-17 and IL-23 antagonist
Molecular Target Interleukin-17 (IL-17) ; Interleukin-23 (IL-23)
Mechanism of Action 
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentDiscovery
Standard Indication Autoimmune (unspecified)
Indication DetailsTreat autoimmune diseases
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today